Development of orally absorbable RNA nanoparticles for cancer immunotherapy
발표자
()
초록
내용
According to a 2022 World Health Organization report, 830,000 of the 10 million cancer deaths are expected to be from Hepatocellular carcinoma (HCC). The cause of the high mortality rate is that early diagnosis of HCC is challenging, and the late onset of symptoms. Existing HCC treatments are administered as intravenous injections, which take 3-4 hours per dose. In addition, it increases the patient's survival time by 2-3 months, but the various side effects rather reduce the patient's quality of life. Therefore, we developed a gene delivery system-based immunotherapy that also enables rapid diagnosis for effective treatment of HCC and improved patient convenience. Rapid diagnosis of HCC with strong fluorescence emission, delivered siRNA significantly reduced PD-L1 expression in HCC, enabling effective immunotherapy with cytotoxic T cells. This system improves patient convenience and quality of life with oral administration.